National Institutes Of Health (NIH)

  • HIV Patients Get Long-Term Boost with Short, Intermittent Drug Regimen
    National Institutes of Health (NIH) scientists report that brief, widely-spaced courses of the experimental immune-boosting drug interleukin-2 (IL-2) allow people with HIV to maintain near normal levels of a key immune system cell for long periods. The researchers, from ...More
    April 27, 2004
    Posted in News
  • Chimerix Awarded NIH Grant to Fund Drug Development for Multi-Drug Resistant HIV Infection
    SAN DIEGO -- Chimerix Inc., a biotechnology company developing orally available, targeted medicines for the treatment of smallpox, multi-drug resistant HIV and hepatitis virus infections, today announced that it has been awarded a Phase I Small Business Innovation Research ...More
    March 11, 2004
    Posted in News
  • Vical to Receive $1 Million in NIH Grants for CMV Vaccine Development
    SAN DIEGO -- Vical Incorporated announces that it has received notification of funding of approximately $1 million for research and development related to the company's plasmid DNA vaccine against cytomegalovirus (CMV) under two grants from the U.S. National Institute of ...More
    March 9, 2004
    Posted in News
  • Scientists Find HIV-Blocking Protein in Monkeys
    WASHINGTON, D.C. -- Scientists at the Dana-Farber Cancer Institute have identified a protein that blocks HIV replication in monkey cells. Humans have a similar protein, although it is not as effective at stopping HIV, say the researchers whose work is published in this ...More
    March 1, 2004
    Posted in News
  • UCSD Medical Center Receives NIH Contract to Set Up National Tuberculosis Educational Curriculum
    SAN DIEGO - Newswise -- The University of California San Diego (UCSD) Department of Medicine, Pulmonary Division, was recently awarded a five-year, $6.2 million contract by the U.S. National Institutes of Health to establish the Tuberculosis Curriculum Coordinating Center ...More
    January 8, 2004
    Posted in News
  • Vical and NIH Developing Ebola Vaccine
    SAN DIEGO -- Vical Incorporated announced today that the company has secured a nonexclusive license from the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services, to proprietary gene sequences used in a DNA vaccine for Ebola, ...More
    November 19, 2003
    Posted in News
  • University of Pittsburgh Receives NIH Funds for Construction of Regional Biosafety Laboratory
    PITTSBURGH -- The University of Pittsburgh has been awarded $18 million from the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, for the construction of a Regional Biocontainment Laboratory (RBL), a biosafety facility ...More
    September 30, 2003
    Posted in News
  • Aventis and NIH Enter Into SARS Vaccine R&D Pact
    LYON, FRANCE -- Aventis has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), to research and develop an inactivated virus vaccine against Severe Acute Respiratory Syndrome ...More
    September 29, 2003
    Posted in News, PPE & Standard Precautions
  • Novavax Selected by NIAID/NIH to Develop HIV Vaccine
    COLUMBIA, Md. -- Novavax Inc. today announced that it was awarded a five year $19.0 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) for the design and development of a new class of human immunodeficiency virus (HIV) vaccine candidates ...More
    September 29, 2003
    Posted in News
  • AlphaVax Receives Two NIH Biodefense Grants
    RESEARCH TRIANGLE PARK, N.C. -- AlphaVax, Inc. has been awarded two National Institutes of Health (NIH) biodefense grants to develop new vaccines, using the company's proprietary technology, against two groups of disease-causing agents that could be used potentially in ...More
    September 29, 2003
    Posted in News
« Previous123456789101112Next »

Video Snapshot

Video Snapshot

Business Case for Infection Prevention

Now Available On-Demand!
Subscribe
Infection Control Today
First Name
 Last Name
E-Mail

Galleries

More ›

ICT Poll

Most Popular Articles

Buyer's Guide

Search for

Reports

 
HOT TOPICS
Related Sites:
ICT Career Connection
Renal Business Today
Surgistrategies
Endonurse
Mobile Healthcare Today